|Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D.||Chief Scientific Officer||205.24k||N/A||N/A|
|Dr. Jason Loveridge B.Sc, Ph.D., FRSM||Corp. Advisor||40k||N/A||N/A|
|Ms. Alison Laws||Chief Exec. Officer||N/A||N/A||N/A|
|Mr. Agha Shahzad Pervez B.Sc.||CFO & Company Sec.||N/A||N/A||N/A|
|Ms. Melanie Baxter||Marketing Director||N/A||N/A||N/A|
Resonance Health Limited, a healthcare company, engages in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment in Asia Pacific, North America, Europe, the Middle East, and Africa. Its flagship product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration. The company also provides Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials, including clinical measurement, as well as project and data management services, such as reporting, administration, and support. The company serves clinicians for the diagnosis and management of human diseases; and pharmaceutical companies for their clinical trials. Resonance Health Limited has a strategic partnership with Perth Radiological Clinic to assess the viability of the development and commercialization of various diagnostic tools. The company is headquartered in Burswood, Australia.
Resonance Health Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.